News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.
The new assay is part of the company's prenatal and women's health offerings, but it is also developing a preeclampsia test and technology for gastrointestinal testing.
To help fund the acquisition, Yourgene Health is planning to sell at least £10.0 million in newly issued shares to institutional investors.
The companies will combine their respective technologies to develop mass spectrometry-based proteomics assays for adverse pregnancy outcomes.
A Chinese study involving NIPS data from almost two million pregnant women found that a new bioinformatic approach improves the detection of cancer.
Yikon's test uses next-generation sequencing to screen embryos for chromosomal aneuploidy prior to implantation and does not require a biopsy.
